文献速递核素与放射性配体治疗肿瘤 PET/CT

PSMA PET/CT衍生指标与[177Lu]Lu-PSMA-617治疗后结局:美国扩大准入计划多中心回顾分析

PSMA PET/CT-Derived Indicators and Outcomes After [177Lu]Lu-PSMA-617: A Multicenter Retrospective Analysis from the U.S. Expanded-Access Program.
PubMed 文献 · J Nucl Med · 2026-05-01

该多中心回顾分析纳入88例接受177Lu-PSMA治疗的mCRPC患者,评估基线PSMA PET/CT视觉与定量指标的预后价值。中位随访36.1个月,PSA50率43%,中位PSA PFS 4.5个月,中位OS 12.5个月。总肿瘤SUVmean对PSA50预测准确性最高(AUC 0.81),且在多因素分析中独立与PSA PFS和OS改善相关。

要点

  • 基线总肿瘤SUVmean越高,PSA PFS和OS越好,且独立于临床因素。
  • 总肿瘤SUVmean对PSA50的预测AUC为0.81,优于其他评估指标。
  • 总肿瘤SUVmean加入临床变量后C指数提升:PSA PFS 0.667 vs 0.594,OS 0.687 vs 0.661。

核心结论

  • 基线PSMA PET/CT总肿瘤SUVmean可提供独立于临床参数的预后信息,可能作为177Lu-PSMA患者选择和个体化治疗的有用生物标志物。

研究设计与样本

  • 回顾性分析纳入来自3家美国机构(UCLA、UCSF、Johns Hopkins)参加扩大准入计划的88例mCRPC患者,均在接受177Lu-PSMA前完成基线PSMA PET/CT。

主要发现

  • 中位随访36.1个月(95%CI 33.8-37.8),PSA50率为43%,中位PSA PFS为4.5个月(95%CI 3.7-7.2),2年PSA PFS率为7%(95%CI 3-16)。
  • 中位OS为12.5个月(95%CI 10.4-17.1),2年OS率为29%(95%CI 20-40)。
  • 总肿瘤SUVmean对PSA50的预测AUC为0.81(95%CI 0.73-0.90),为所评估指标中最高。
  • 多因素分析中,较高的总肿瘤SUVmean独立与PSA PFS改善相关(HR 0.58,95%CI 0.39-0.86,P=0.007),并与OS改善相关(HR 0.54,95%CI 0.34-0.86,P=0.009)。
  • 总肿瘤SUVmean相较仅临床变量模型具有更高的C指数(PSA PFS 0.667 vs 0.594;OS 0.687 vs 0.661)。

关键数值与推荐

  • 总肿瘤SUVmean对PSA50的AUC为0.81(95%CI 0.73-0.90)。
  • 总肿瘤SUVmean与PSA PFS的HR为0.58(95%CI 0.39-0.86,P=0.007),与OS的HR为0.54(95%CI 0.34-0.86,P=0.009)。
  • 总肿瘤SUVmean模型的C指数:PSA PFS 0.667,OS 0.687;临床变量模型分别为0.594和0.661。

临床怎么用

  • 在接受177Lu-PSMA治疗前,可利用基线PSMA PET/CT测量总肿瘤SUVmean,辅助评估预后和筛选可能获益的患者。

局限性

  • 本文为回顾性分析,样本量88例,来自3家美国机构,结论需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pretherapeutic visual and quantitative indicators derived from prostate-specific membrane antigen (PSMA) PET/CT have been proposed as predictors of response to [177Lu]Lu-PSMA-617 (177Lu-PSMA) therapy in patients with metastatic castration-resistant prostate cancer. This study aimed to evaluate and compare the prognostic performance of these indicators in a cohort treated under the U.S. Expanded-Access Program. Methods: This retrospective analysis included 88 patients with metastatic castration-resistant prostate cancer from 3 U.S. institutions (University of California Los Angeles, University of California San Francisco, and Johns Hopkins) enrolled in the Expanded-Access Program who underwent baseline PSMA PET/CT before receiving 177Lu-PSMA. We assessed visual indicators-such as the visual PSMA PET tumor-to-salivary gland ratio, tumor heterogeneity, and intensity scores-and quantitative metrics including total tumor volume (TTV), total tumor SUVmean, total tumor SUVmax, total lesion uptake (TTV × total tumor SUVmean), total lesion quotient (TTV ÷ total tumor SUVmean), and the quantitative PSMA PET tumor-to-salivary gland score. Associations with clinical outcomes-a 50% or greater prostate-specific antigen decline (PSA50), prostate-specific antigen (PSA) progression-free survival (PFS), and overall survival (OS)-were analyzed using univariate and multivariate models. Predictive performance was evaluated via the concordance index from Cox proportional hazards regression. Results: After a median follow-up of 36.1 mo (95% CI, 33.8-37.8 mo), the PSA50 rate was 43%, the median PSA PFS was 4.5 mo (95% CI, 3.7-7.2 mo), and the 2-y PSA PFS rate was 7% (95% CI, 3-16%). The median OS was 12.5 mo (95% CI, 10.4-17.1 mo), and the 2-y OS rate was 29% (95% CI, 20-40%). Among the evaluated metrics, total tumor SUVmean showed the highest predictive accuracy for PSA50 (area under the curve, 0.81; 95% CI, 0.73-0.90). In multivariate analyses adjusted for clinical factors, a higher total tumor SUVmean was independently associated with improved PSA PFS (hazard ratio, 0.58; 95% CI, 0.39-0.86; P = 0.007) and OS (hazard ratio, 0.54; 95% CI, 0.34-0.86; P = 0.009). Total tumor SUVmean also yielded higher concordance index values compared with models based on clinical variables alone (PSA PFS, 0.667 vs. 0.594; OS, 0.687 vs. 0.661, respectively). Conclusion: Baseline total tumor SUVmean on PSMA PET/CT provides independent prognostic information beyond clinical parameters and may serve as a useful biomarker for patient selection and treatment personalization with 177Lu-PSMA.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kimura K, Murthy V, Voter AF, et al. PSMA PET/CT-Derived Indicators and Outcomes After [177Lu]Lu-PSMA-617: A Multicenter Retrospective Analysis from the U.S. Expanded-Access Program. J Nucl Med. 2026. PMID: 41679922. doi:10.2967/jnumed.125.270789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。